TrialInflammatory bowel diseases2022

Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab.

Parambir S Dulai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.